Evidence map›Paper›PMID 8642700›Full record

ArticleJournal of virology1996

Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

D C Porter, L R Melsen, R W Compans, C D Morrow

Abstract read
In one paragraph

Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Viral vectors for veterinary vaccines.Advances in veterinary medicine · 1999
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

D C PorterDepartment of Microbiology, University of Alabama at Birmingham, Alabama 35294, USA.
L R Melsen
R W Compans
C D Morrow

Funding

Novel VLP-Based Mucosal and Sytemic HIV VaccinesU19AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2003 to 2009
$15.8M
EXPRESSION OF FUNCTIONAL POLIOVIRUS REPLICATION PROTEINSR01AI025005 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MORROW, CASEY D · 1987 to 2002
$715k
EXPRESSION OF FUNCTIONAL POLIOVIRUS REPLICATION PROTEINSR21AI025005 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MORROW, CASEY D · 1997 to 1997
–
RECOMBINANT VACCINES DERIVED FROM POLIOVIRUSU01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MASTECKY, JIRI · 1989 to 1997
–
NIAID NIH HHS AI15128NIAID NIH HHS AI25005NIAID NIH HHS AI28147
6 · The paper itself

Abstract

The effectiveness of attenuated poliovirus vaccines when given orally to induce both systemic and mucosal immune responses against poliovirus has resulted in an effort to develop poliovirus-based vectors to express foreign proteins. We have previously described the construction of poliovirus genomes (referred to as replicons) in which the complete human immunodeficiency virus type 1 (HIV-1) gag gene was substituted for the capsid gene (P1) (D.C. Porter, D.C. Ansardi, and C.D. Morrow, J. Virol. 69:1548-1555, 1995). Infection of cells with encapsidated replicons resulted in the expression of a 55-kDa protein. To further characterize the biological features of the HIV-1 Gag proteins expressed in cells infected with encapsidated replicons, we utilized biochemical analysis and electron microscopy. Expression of the 55-kDa protein in cells infected with encapsidated replicons resulted in myristylation of the Pr55gag protein. The Gag precursor protein was released from infected cells; analysis on sucrose density gradients revealed that the precursor sedimented at a density consistent with that of an HIV-1 virus-like particle. Analysis of replicon-infected cells by electron microscopy demonstrated the presence of condensed structures at the plasma membrane and the release of virus-like particles. These studies demonstrate that poliovirus-based vectors can be used to express foreign proteins which require posttranslational modifications, such as myristylation, and assemble into higher-order structures, providing a foundation for the future use of poliovirus replicons as vaccine vectors.

Indexed as

Genetic VectorsAmino Acid SequenceGene Products, gagHeLa CellsHIV-1HumansMolecular Sequence DataMyristic AcidMyristic AcidsPoliovirusProtein PrecursorsProtein Processing, Post-TranslationalRecombinant ProteinsRepliconVirus ReplicationGene Products, gagMyristic AcidMyristic Acidsp55 gag precursor protein, Human immunodeficiency virus 1Protein PrecursorsRecombinant Proteins

Identifiers

PMID8642700
PMCPMC190116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.